Key takeaways from the J.P. Morgan Health Conference 2024: Promising fundraising outlook

Like every year, 2024 kicked off with a bang for the biotech industry, as thousands gathered at the J.P. Morgan Health Conference (JPM) that took place in San Francisco, last week. One of the largest healthcare conventions in the world, JPM recaps the glories as well as the gloom of the past year, and sets the stage for what’s to come. 

Here are some of the key takeaways from the JPM conference that lay the groundwork for what we can expect in 2024.

On the fundraising front, 2024 might be more promising compared to 2023. 

“The discussion during 2023 was VCs were holding back on new investments keeping their ‘powder dry’ for existing portfolio companies, in case additional funding was needed,” said Jeremy Skillington, CEO of Poolbeg Pharma.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:

More articles like this

POLB 001: Targeting CRS in Cancer Immunotherapy

Phase 2 Ready orally administered p38 MAP Kinase inhibitor – a preventative therapy targeting an addressable market of more than $10 billion. POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer

Poolbeg Pharma updates on Immunomodulator II Patent

Poolbeg Pharma has announced that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a precursor to the expected formal grant

February hires in Pharma

February may be the shortest month, but we got an extra day this year and that left plenty of time for personnel announcements in the pharma world. Read on for a roundup of the month’s hiring

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a